TNFAIP3 and cancer: Comprehensive analyses included: (1) differential expression across cancer types and BRCA subtypes; (2) correlation with clinicopathological features; (3) survival analysis using Kaplan–Meier and Cox regression; (4) immune cell infiltration assessment via ssGSEA; and (5) co‐expression analysis of TNFAIP3‐LINC01096.